Zongertinib (BI 1810631)

DRUG2 trials

Sponsors

Boehringer Ingelheim, MedSIR

Conditions

Advanced Breast CancerHER2 MutationHealthyHormone Receptor Positive / HER2-negative Breast CancerLiver Diseases

Phase 1

A Study to Test How Zongertinib is Taken up in the Blood of People With and Without Liver Problems

CompletedNCT06692322

Boehringer IngelheimHealthy, Liver Diseases

Start: 2025-01-15End: 2025-06-20Updated: 2025-08-15

Phase 2

A Phase II Study of Zongertinib Plus Fulvestrant in Participants With HR-positive/HER2-negative Advanced Breast Cancer Harboring HER2 Mutations.

Not yet recruitingNCT07619066

MedSIRAdvanced Breast Cancer, HER2 Mutation, Hormone Receptor Positive / HER2-negative Breast Cancer

Start: 2026-10-04End: 2028-11-28Target: 25Updated: 2026-06-01